Mayinglong Pharmaceutical Group Co., Ltd. Class A

Mayinglong Pharmaceutical Group Co., Ltd. Class A

SSSE:600993
26.20
CNY
+0.96
(+3.80%)
1.44EPS
16.35P/E
9.71BMarket Cap
Mar 25Next Earn

Total Valuation

CNY

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 9.71B, placing it among publicly traded companies globally. Its enterprise value stands at 7.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap9.71B
Enterprise Value7.51B

Important Dates

Mayinglong Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for March 25, 2027.

Earnings Date3/25/2027

Share Statistics

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A has 431.05M shares outstanding.

Shares Outstanding431.05M

Valuation Ratios

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 16.35. The price-to-sales ratio is 2.44, and the price-to-book ratio stands at 2.11.

PE Ratio16.35
PS Ratio2.44
PB Ratio2.11
P/TBV Ratio2.24

Enterprise Valuation

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 10.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.51B versus a market cap of 9.71B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.88
EV / EBITDA10.19
EV / EBIT10.19

Financial Position

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 4.65, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.51, indicating elevated leverage, while an interest coverage ratio of 149.62 demonstrates strong ability to service its debt obligations.

Current Ratio4.65
Quick Ratio3.02
Debt / Equity1.51
Debt / EBITDA0.10
Interest Coverage149.62

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A posted a return on equity (ROE) of 13.62, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.37, useful for judging operating efficiency across full business cycles. The company generates approximately 1.57M in revenue per employee across its workforce of 2,544.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.31 indicates how many times Mayinglong Pharmaceutical Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)13.62
Return on Assets (ROA)10.55
Return on Invested Capital (ROIC)13.19
Return on Capital Employed (ROCE)12.37
Revenue Per Employee1.57M
Employee Count2,544.00
Inventory Turnover7.31

Taxes

CNY

Over the twelve months ended September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A recorded 106.92M in income tax expense. That works out to an effective tax rate of 14.70, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 727.49M, leaving 594.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax106.92M
Effective Tax Rate14.70

Stock Price Statistics

CNY

As of the close on November 17, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 6.53% over the past 52 weeks. The 50-day moving average sits at 23.63, while the 200-day moving average is 24.58.

52-Week Price Change-6.53%
50-Day Moving Average23.63
200-Day Moving Average24.58

Income Statement

CNY

Over the twelve months ended September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A generated 3.99B in revenue and converted that into 594.83M in net income, yielding earnings per share of 1.44. EBITDA reached 737.01M, while operating income came in at 691.00M.

Revenue3.99B
Gross Profit1.86B
Operating Income691.00M
Pretax Income727.49M
Net Income594.83M
EBITDA737.01M
EBIT737.01M
Earnings Per Share (EPS)1.44

Balance Sheet

CNY

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A holds 2.40B in cash and equivalents against 71.29M in total debt, resulting in a net debt position of -557.11M. Total book value stands at 4.59B, with working capital of 2.90B providing operational flexibility.

Cash & Cash Equivalents2.40B
Total Debt71.29M
Net Debt-557.11M
Equity (Book Value)4.59B
Book Value Per Share10.65
Working Capital2.90B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-106.45M

Margins

Over the twelve months ended September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 46.71, reflecting its pricing power and cost economics. The operating margin of 17.32 and net profit margin of 14.91 provide insight into operational efficiency.

Gross Margin46.71
Operating Margin17.32
Pretax Margin18.23
Profit Margin14.91
EBITDA Margin18.47

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.70 per share. The dividend payout ratio of 46.76 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mayinglong Pharmaceutical Group Co., Ltd. Class A shareholders.

Dividend Per Share0.70
Payout Ratio46.76
Shareholder Yield4.14

Stock Splits

Mayinglong Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on July 21, 2015 with a 10:13 split ratio.

Last Split Date7/21/2015
Split Ratio10:13

Scores

As of September 30, 2026, Mayinglong Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 9.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.11